Medication info

Itex Valsartan Tablet 80 mg

Prescription medicationExpired
Ingredient · strength
Valsartan›Strength being verified
Manufacturer / importer
TerraGen Itext Co., Ltd.
Appearance
Orange round film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Expired

MFDS item code 201307904 · Approved 2013.06.28

This product's status changed to Expired on 2023.06.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treats essential hypertension and heart failure; reduces the risk of death after myocardial infarction
Who uses it
Adults · Children
Adult dosage
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that this medication be taken at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, oral administration of 80 mg of valsartan once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Start treatment with 40 mg of this medication once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medication once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medication once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medication once daily; the dose should not exceed 80 mg daily. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medication orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When co-administering a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of mortality risk after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medication twice daily. Over the following weeks, the dose may be increased, depending on the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medication. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is advisable not to exceed a daily dose of 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Children's dosage
6) Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
TerraGen Itext Co., Ltd.

Efficacy & effects

Treats essential hypertension and heart failure; reduces the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
View approved original text

This medication is used to treat essential hypertension. It is also effective in heart failure patients (NYHA Class II to IV) who are intolerant to ACE inhibitors. It is utilized to reduce the risk of death from left ventricular dysfunction following myocardial infarction. Thus, it is a medication that helps manage hypertension as well as prevent complications associated with heart failure and myocardial infarction. It is used to improve cardiovascular health in patients with these efficacies.

Dosage and Administration

Adult dosage

1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that this medication be taken at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, oral administration of 80 mg of valsartan once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Start treatment with 40 mg of this medication once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medication once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medication once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medication once daily; the dose should not exceed 80 mg daily. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medication orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When co-administering a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of mortality risk after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medication twice daily. Over the following weeks, the dose may be increased, depending on the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medication. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is advisable not to exceed a daily dose of 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Children's dosage

6) Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, and should be immediately discontinued if pregnancy is confirmed. People with allergies to this drug or its components, pregnant or possibly pregnant women, nursing mothers, patients with severe liver disease, patients with a history of hereditary angioedema, patients with severe renal impairment, and patients with certain endocrine disorders should not take this medication. Elderly patients, those with elevated potassium levels, those with slightly impaired liver function, patients with heart diseases, and patients with dehydration should exercise particular caution when using this drug, starting at a lower dose and monitoring their condition closely. Side effects may include headaches, dizziness, fatigue, cough, and dyspepsia; serious and rare side effects such as severe angioedema, renal function deterioration, hepatitis, hypoglycemia, and muscle disorders may occur, necessitating immediate consultation with a doctor. If blood pressure drops rapidly, leading to dizziness or fainting, treatment should be ceased immediately and appropriate care sought, especially for those on diuretics or with dehydration. Regular blood tests are necessary when taken with other antihypertensives, diuretics, or potassium supplements, as potassium levels may become excessively elevated. It is advisable for pregnant or nursing women to avoid this medication; if nursing, it is preferable to discontinue either the drug or breastfeeding. Safety regarding use in children or adolescents under the age of 18 has not been established, hence, its use is not recommended. In cases of overdose, serious hypotension or decreased consciousness may occur, requiring immediate medical attention. This medication should be stored out of reach of children and should not be transferred to other containers to ensure safety.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain its efficacy.

Appearance and packaging

Appearance

Orange round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.